Familial hypercholesterolaemia trials in China

In China 20 Also abroad 115

20 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Where
Beijing, Guangzhou, Hangzhou, Shanghai
Age
6 years to 17 years
People
153 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07058077 · EU 2024-519068-42-00
No phaseTaking people
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
Where
Dalian
Age
18 years and over
People
2,000 worldwide
Run by
Stephen Nicholls
See details and how to joinNCT05325034
Early phase 1Taking people
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
Where
Xi'an
Age
12 years to 55 years
People
21
Run by
First Affiliated Hospital Xi'an Jiaotong University
See details and how to joinNCT06125847
Phase 2Taking people
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
Where
Changsha
Age
18 years and over
People
18
Run by
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07591298
Phase 3Taking people
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Where
Beijing
Age
2 years to 11 years
People
9 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06597006
Phase 3Taking people
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Where
Beijing
Age
18 years and over
People
135
Run by
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07465263
Phase 4Not yet taking people in China
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
Where
Changsha
Age
18 years and over
People
29
Run by
Hunan Cancer Hospital
See details and how to joinNCT07674368
Phase 2/3Taking people
A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
Where
Nanjing
Age
18 years to 85 years
People
126
Run by
Beijing Suncadia Pharmaceuticals Co., Ltd
See details and how to joinNCT07404553
Phase 2Taking people
A Dose-exploration Study of EDP167 in HoFH
Where
Beijing
Age
18 years and over
People
20
Run by
Eddingpharm (Zhuhai) Co., Ltd.
See details and how to joinNCT07489209
No phaseTaking people
Child-Parent Familial Hypercholesterolemia Screening
Where
Chongqing, Hefei, Qidong, Shanghai, Taiyuan, Ürümqi
Age
1 year to 3 years
People
15,000
Run by
Children's Hospital of Fudan University
See details and how to joinNCT04529967
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Where
Beijing, Shanghai
Age
6 years to 11 years
People
60 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06597019
Phase 3Taking people
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Where
Beijing
Age
18 years and over
People
760
Run by
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07421297
Early phase 1Not yet taking people in China
Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy
Where
Shanghai
Age
18 years to 70 years
People
24
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07353398
Phase 3Not yet taking people in China
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
Where
Beijing
Age
18 years and over
People
900
Run by
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07421284
Phase 2Not yet taking people in China
Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
Where
Changsha
Age
12 years and over
People
55
Run by
Beijing Suncadia Pharmaceuticals Co., Ltd
See details and how to joinNCT07133815
Phase 1Not yet taking people in China
Pharmacokinetics and Pharmacodynamics Study
Where
Qingdao
Age
18 years to 65 years
People
48
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07074236
Early phase 1Taking people
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
Where
Shanghai
Age
18 years to 75 years
People
20
Run by
RenJi Hospital
See details and how to joinNCT06458010
Phase 1Enrolling by invitation
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
Where
Chengdu
Age
18 years to 55 years
People
30
Run by
Hasten Biopharmaceutical Co., Ltd.
See details and how to joinNCT06504043
Phase 3Taking people
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Where
Beijing, Binzhou, Changsha, Chengdu, Daqing, Guangzhou, Heze, Jinan, Nanchang, Shijiazhuang, Tianjin, Wenzhou, Zibo
Age
18 years and over
People
210
Run by
Hasten Biopharmaceutical Co., Ltd.
See details and how to joinNCT06568471
Phase 1Not yet taking people in China
Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH
Where
Xi'an
Age
18 years to 45 years
People
30
Run by
Tang-Du Hospital
See details and how to joinNCT05043181